PCV24 A Threshold Analysis of the Cost-Effectiveness of Adjunctive Inclisiran Therapy for Ascvd Patients with LDL ≥70 MG/DL on Maximally Tolerated Statin Therapy

Abstract

Inclisiran is a first-in-class, small-interfering ribonucleic acid (siRNA) that has been recently submitted to the Food and Drug Administration (FDA) for approval for the treatment of atherosclerotic cardiovascular disease (ASCVD) in patients with low-density lipoprotein (LDL) ≥70 mg/dL despite being on maximally tolerated statin therapy. We created a Markov model to estimate a range of value-based prices for inclisiran compared to currently available therapies: ezetimibe and the proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9s).